NEW YORK, March 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Dermatological Drugs: World Market Prospects 2012-2022
http://www.reportlinker.com/p0788690/Dermatological-Drugs-World-Market-Prospects-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
Report Details
Where are dermatological treatments heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions.
This study assesses drugs to treat human skin disorders. You discover sales predictions at world market, therapeutic submarket, product and national levels to 2022.
How will 24 leading drugs - Valtrex, Zovirax, Protopic, Enbrel and others - perform from 2012? Our report gives you business research and analysis with many sales forecasts.
Also, you see forecasting of five derma submarkets to 2022, finding potential revenues:
• Dermatitis
• Psoriasis
• Acne
• Infectious skin diseases
• Miscellaneous dermatologics.
What does the future hold? The pharma industry has potential for improved treatments and increased revenues from dermatological agents. The R&D pipeline is strong.
Our report discusses GSK, Galderma, Amgen, Abbott, J&J and other pharmaceutical companies, assessing prospects of the industry and market.
Many commercial opportunities in treating skin disorders remain, including increased revenues. You can investigate the future of that area now.
Visiongain's study provides data, analysis and opinion aiming to benefit your research, calculations, meetings and presentations. You find answers in our work.
Revenue forecasts, market shares, developmental trends and discussions
In our report you find revenue forecasting, growth rates and market shares. Also, you have qualitative analyses (including SWOT) and discussion of R&D activities. You receive 121 tables and charts and a research interview.
Advantages of Dermatological Drugs: World Market Prospects 2012-2022 for your work
In particular, this study gives you the following knowledge on the topic:
• Find potential revenues to 2022 for the world market and submarkets
• Discover revenue forecasts to 2022 for 24 leading products
• See market forecasting to 2022 for the US, Japan, the EU5, China and India
• Assess leading companies, discovering activities and outlooks
• Review R&D, seeing pipeline trends
• Investigate competition and opportunities influencing sales
• Find out what will stimulate and restrain the industry and market
• View opinion from the sector, receiving primary research.
There, you find a distinctive mix of quantitative and qualitative analyses with independent predictions. Without our report, you could miss out on information that your competitors are using.
We investigate commercial applications of dermatology, helping you to stay ahead.
Gain business research and analysis for the treatment of skin disorders
Our study is for everybody needing industry and market analyses for dermatological drugs. Find data, trends and answers. Avoid missing out - please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Table of Contents
1. Executive Summary
1.1 World Dermatological Drug Market: Overview of Findings
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods
2. Introduction to Dermatological Disorders and Their Treatments
2.1 An Introduction to Dermatology
2.1.1 The Structure of the Skin
2.1.2 Hair
2.1.3 Nails
2.1.4 Sweat and Sebaceous Glands
2.2 Functions of the Skin
2.2.1 Protection
2.2.2 Sensation
2.2.3 Vitamin D Synthesis
2.2.4 Temperature Regulation and Heat Insulation
2.2.5 Storage
2.2.6 Prevention of Water Loss
2.3 Common Skin Diseases
2.4 An Introduction to Acne Vulgaris
2.4.1 Acne Conglobata
2.4.2 Acne Fulminans
2.4.3 Gram-Negative Folliculitis
2.4.4 Pyoderma Faciale
2.4.5 Causes of Acne
2.5 An Introduction to Dermatitis
2.5.1 Atopic Dermatitis
2.5.2 Contact Dermatitis
2.5.3 Seborrheic Dermatitis
2.5.4 Nummular Dermatitis
2.5.5 Perioral Dermatitis
2.6 An Introduction to Psoriasis
2.6.1 Plaque Psoriasis
2.6.2 Guttate Psoriasis
2.6.3 Pustular Psoriasis
2.6.4 Inverse Psoriasis
2.6.5 Erythrodermic Psoriasis
2.7 An Introduction to Rosacea
2.7.1 Erythematotelangiectatic Rosacea
2.7.2 Papulopustular Rosacea
2.7.3 Phymatous Rosacea
2.7.4 Ocular Rosacea
2.8 An Introduction to Alopecia
2.8.1 Alopecia Areata
2.8.2 Alopecia Totalis
2.8.3 Alopecia Universalis
2.8.4 Androgenetic Alopecia
2.8.5 Alopecia Barbae
2.8.6 Alopecia Mucinosa
2.8.7 Traction Alopecia
2.8.8 Anagen Effluvium
2.8.9 Telogen Effluvium
2.9 An Introduction to Infectious Diseases of the Skin
2.9.1 Bacterial Skin Infections
2.9.1.1 Impetigo
2.9.1.2 Folliculitis
2.9.1.3 Cellulitis
2.9.1.4 Furunculosis
2.9.1.5 Carbuncle
2.9.2 Fungal Skin Infections
2.9.2.1 Tinea Pedis (Athlete's Foot)
2.9.2.2 Tinea Unguium (Ringworm of the Nails)
2.9.2.3 Tinea Corporis (Ringworm of the Skin)
2.9.2.4 Tinea Capitis (Scalp Ringworm)
2.9.2.5 Kerions
2.9.3 Viral Skin Infections
2.9.3.1 Molluscum Contagiosum
2.9.3.2 Warts
2.9.3.3 Herpes Simplex
2.9.3.4 Chickenpox
2.9.3.5 Herpes Zoster
2.10 Common Skin Treatments
2.10.1 Creams and Semisolid Emulsions
2.10.2 Ointments
2.10.3 Lotions
2.10.4 Solutions
2.10.5 Occlusive Therapy
2.10.6 Cleansing Agents
2.10.7 Protecting Powders and Hydrophilic Polymer
2.10.8 Anti-Infective Agents
2.10.9 Anti-Inflammatory Agents
3. The World Dermatological Drug Market, 2012-2022
3.1 The World Dermatological Drug Market in 2010
3.2 The Infectious Skin Diseases Market Dominates the World Dermatological Drug Market
3.3 Biologic Agents for the Treatment of Psoriasis Are the Leading Drugs in the Dermatologics Market
3.4 The Changing Landscape of the Dermatological Drug Market
3.5 The World Dermatological Drug Market: Forecasts, 2012-2022
3.5.1 Market Shares of Leading Segments
3.5.1.1 The Psoriasis Market Will Achieve the Greatest Increase in Market Share
3.6 The Future of the Dermatological Drug Market
3.6.1 Blockbuster Sales - Hard to Achieve?
4. The Infectious Skin Diseases Drug Market, 2012-2022
4.1 The Infectious Skin Diseases Drug Market in 2010
4.1.1 Antiviral Products Led the Dermatological Anti-Infectives Market in 2010
4.1.2 Systemic Antiviral Products Lead the Infectious Skin Diseases Drug Market
4.2 World Infectious Skin Diseases Drug Market Forecast, 2012-2022
4.3 Valtrex (Valacyclovir)
4.3.1 Patent Expiry and the End of Blockbuster Revenues
4.3.2 Valtrex Sales Will Continue to Decline
4.4 Zovirax
4.4.1 Zovirax Sales Forecast, 2012-2022
4.5 Aldara/Zyclara (Imiquimod)
4.5.1 Patent Expiry and Other Challenges
4.5.2 Lifecycle Management
4.5.3 Aldara Sales Forecast, 2012-2022
4.6 Bactroban (Mupirocin)
4.6.1 Bactroban Sales Forecast, 2012-2022
4.7 Lamisil (Terbinafine)
4.7.1 Lamisil Sales Forecast, 2012-2022
4.8 The Infectious Skin Diseases Market - Summary
5. The Dermatitis Drug Market, 2012-2022
5.1 The Dermatitis Drug Market in 2010
5.1.1 Corticosteroids are the Leading Dermatitis Treatment
5.2 Dermatitis Drug Market Forecast, 2012-2022
5.3 Protopic (Tacrolimus)
5.3.1 Protopic Sales Forecast, 2012-2022
5.3.2 Protopic Benefits from Expanded Indication
5.3.3 Will Protopic's Strong Sales Increase Recur?
5.4 Elidel (Pimecrolimus)
5.4.1 Elidel Rights Sold
5.4.2 Regulatory Matters
5.4.3 Elidel Sales Forecast, 2012-2022
5.4.4 Expanding Elidel Indications May Stimulate Sales Growth
5.5 Elocon (Mometasone Furoate)
5.5.1 Elocon Sales Forecast, 2012-2022
5.6 Clob X/Clobex (Clobetasol Propionate)
5.6.1 Clobex Sales Increase
5.7 Soriatane (Acitretin)
5.8 The Dermatitis Drug Market - Summary
6. The Psoriasis Drug Market, 2012-2022
6.1 The Psoriasis Drug Market in 2010
6.2 Biologic Drugs Lead the Psoriasis Market
6.3 World Psoriasis Drug Market Forecast, 2012-2022
6.3.1 Growth in the Psoriasis Drug Market Will Be Spurred by Increasing Use of Biologics
6.4 Enbrel (Etanercept)
6.4.1 Enbrel Continued to Lead the Psoriasis Market in 2010
6.4.2 Enbrel Sales Forecast, 2012-2022
6.4.3 Enbrel in Competition with Humira and Stelara
6.4.4 Biosimilar Competition
6.4.5 Competition from Pipeline Products
6.5 Humira (Adalimumab)
6.5.1 Humira Has Gained Market Acceptance
6.6 Stelara (Ustekinumab)
6.6.1 Stelara Will Achieve Strong Growth in the Psoriasis Market
6.7 Remicade (Infliximab)
6.8 Topical Treatments for Psoriasis
6.9 Daivobet (Calcipotriol and Betamethasone)
6.9.1 Daivobet Leads the Topical Psoriasis Market
6.9.2 Daivobet Sales Will Grow Until 2020
6.10 Taclonex (Calcipotriol and Betamethasone)
6.10.1 Taclonex Sales Forecast, 2012-2022
6.10.2 Taclonex May Face Generic Competition
6.11 Dovonex (Calcipotriol)
6.11.1 Patent Expiration and Generic Competition
6.11.2 Dovonex Sales Forecast, 2012-2022
6.12 The World Psoriasis Drug Market - Summary
7. The Acne Drug Market, 2012-2022
7.1 Available Treatments and Unmet Needs
7.2 Leading Products in the Acne Drug Market, 2010
7.3 World Acne Drug Market Forecast, 2012-2022
7.4 Claravis (Isotretinoin)
7.4.1 Claravis Sales Forecast, 2012-2022
7.5 Solodyn (Minocycline)
7.5.1 Solodyn Led the World Acne Drug Market in 2010
7.5.2 Solodyn Sales Forecast, 2012-2022
7.6 Diane (Cyproterone and Ethinylestradiol)
7.6.1 Diane Sales Forecast, 2012-2022
7.7 Duac (Clindamycin and Benzoyl Peroxide)
7.8 Doryx (Doxycycline Hyclate)
7.8.1 Doryx Sales Forecast, 2012-2022
7.8.2 Lifecycle Management of Doryx
7.9 Differin (Adapalene)
7.9.1 Differin Sales Forecast, 2012-2022
7.9.2 Lifecycle Management of Differin
7.10 Combination Treatments for Acne
7.10.1 Epiduo (Adapalene and Benzoyl Peroxide)
7.10.2 Ziana (Tretinoin and Clindamycin)
7.10.3 Veltin (Tretinoin and Clindamycin)
7.11 The World Acne Drug Market - Summary
8. Miscellaneous Dermatological Drugs, 2012-2022
8.1 The Miscellaneous Dermatological Drugs Market in 2010
8.2 Miscellaneous Dermatological Drugs: Market Forecast, 2012-2022
8.3 Propecia (Finasteride)
8.3.1 Propecia Sales Will Fall
8.3.2 Propecia Faces Competition from Rogaine/Regaine
8.4 The Miscellaneous Dermatological Drugs Market - Summary
9. Leading Companies in the Dermatological Drug Market
9.1 Prominent Companies in the Dermatological Drug Market, 2010
9.2 GlaxoSmithKline
9.3 Galderma
9.4 Amgen
9.5 Abbott
9.6 Johnson & Johnson
9.7 Medicis Pharmaceutical
9.8 LEO Pharma
9.9 Warner Chilcott
9.10 Valeant
9.11 Roche
9.12 Sanofi
9.13 Bayer
9.14 Merck & Co.
9.15 Meda AB
9.16 Novartis
9.17 Companies in the Dermatological Drug Market - Summary
10. The R&D Pipeline for Dermatological Pharmaceuticals
10.1 The Size of the Dermatological Pharmaceuticals Market Encourages R&D
10.2 New Technology in R&D Pipeline Activities
10.2.1 Reformulation
10.2.2 Combination Treatments
10.2.3 New Mechanisms and Drug Delivery Technologies
10.3 Potential Market Entrants
10.4 The Infectious Skin Disease Pipeline
10.4.1 NB-001
10.5 The Dermatitis Pipeline
10.5.1 MRX6
10.6 The Psoriasis Pipeline
10.6.1 Briakinumab
10.6.2 Apremilast
10.6.3 AN2728
10.6.4 Tofacitinib
10.7 The Acne Pipeline
10.7.1 Visonac
10.7.2 Acne Vaccine
10.7.3 ACAT Inhibitor
10.8 The Miscellaneous Dermatological Drugs Pipeline
10.9 PEP005
10.10 Innovation Rules for Early-Stage Pipeline Drugs
11. National Market Forecasts, 2012-2022
11.1 Leading National Markets for Dermatological Drugs, 2010
11.2 Leading National Markets for Dermatological Drugs: Forecasts, 2012-2022
11.3 The Dermatological Drug Market in the US, 2012-2022
11.4 The Dermatological Drug Market in Japan, 2012-2022
11.5 The Dermatological Drug Market in Germany, 2012-2022
11.6 The Dermatological Drug Market in France, 2012-2022
11.7 The Dermatological Drug Market in the UK, 2012-2022
11.8 The Dermatological Drug Market in Italy, 2012-2022
11.9 The Dermatological Drug Market in Spain, 2012-2022
11.10 The Dermatological Drug Market in India, 2012-2022
11.11 The Dermatological Drug Market in China, 2012-2022
12. Qualitative Analysis of the World Dermatological Drug Market, 2012
12.1 SWOT Analysis
12.2 Market Drivers
12.3 Market Restraints
12.4 There is Scope for Market Development and Expansion
12.5 Advances in Research are Likely to Bring Benefits to the Market
12.6 Downward Pressures on Drug Prices Affect the Industry
12.7 Competition in the Dermatological Drug Market Will Intensify
12.8 Substitutes
12.9 How Great is the Threat from Generic Drugs in the Dermatological Sector?
13. Research Interview
13.1 Interview with Dr Adam Friedman
13.1.1 Unmet Needs in the Dermatological Drugs Marks
13.1.2 Key Areas for Dermatological Research
13.1.3 Pipeline Dermatological Drug Products
13.1.4 The Future Role of Nanotechnology in Dermatological Drugs
13.1.5 Challenges in Advancing Dermatological Treatments
14. Conclusions
14.1 The World Dermatological Drug Market Will Experience Sales Growth
14.2 Will The Infectious Skin Diseases Market Continue to Dominate the Overall Market?
14.3 Dermatological Treatments: Companies Prominent in that Industry and Market
14.4 The Need for New Therapies for the Treatment of Dermatitis
14.5 Combination Treatments and Lifecycle Management in the Acne Market
14.6 Biologics Will Drive Growth in the Psoriasis Market
14.7 Overall World Dermatological Drug Market Growth Will Continue
List of Tables
Table 3.1 The World Dermatological Drugs: Market Segments, Revenues ($m) and Market Shares (%), 2010
Table 3.2 Leading Dermatological Drugs ($m), 2010
Table 3.3 World Dermatological Drug Market: Sales Forecasts by Segment ($m), AGR (%), CAGR (%), 2010-2016
Table 3.4 World Dermatological Drug Market: Sales Forecasts by Segment ($m), AGR (%), CAGR (%), 2017-2022
Table 3.5 Segments of the World Dermatological Drug Market: Forecasts by Market Share (% of Total Revenues), Rank (By Revenue), 2010, 2016 and 2022
Table 4.1 Leading Drugs for the Treatment of Infectious Skin Diseases ($m), 2010
Table 4.2 Sales ($m) and Market Shares (%) of Infectious Skin Diseases Drugs by Class, 2010
Table 4.3 Infectious Skin Disease Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2010-2016
Table 4.4 Infectious Skin Disease Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2017-2022
Table 4.5 Valtrex Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 4.6 Zovirax Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 4.7 Aldara Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 4.8 Bactroban Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 4.9 Lamisil Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 5.1 Leading Drugs ($m) for the Treatment of Dermatitis, 2010
Table 5.2 Sales ($m) and Market Shares (%) of Dermatitis Drugs by Class, 2010
Table 5.3 Dermatitis Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2010-2016
Table 5.4 Dermatitis Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2017-2022
Table 5.5 Protopic Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 5.6 Elidel Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 5.7 Elocon Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 5.8 Clobex Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 5.9 Soriatane Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 6.1 Market Leading Drugs ($m) for the Treatment of Psoriasis, 2010
Table 6.2 Psoriasis Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2010-2016
Table 6.3 Psoriasis Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2017-2022
Table 6.4 Enbrel Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 6.5 Humira Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 6.6 Stelara Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 6.7 Remicade Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 6.8 Daivobet Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 6.9 Taclonex Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 6.10 Dovonex Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 7.1 Acne Drug Sales ($m) by Class, 2010
Table 7.2 Market Leading Drugs ($m) for the Treatment of Acne, 2010
Table 7.3 Acne Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2010-2016
Table 7.4 Acne Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2017-2022
Table 7.5 Claravis Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 7.6 Solodyn Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 7.7 Diane Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 7.8 Duac Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 7.9 Doryx Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 7.10 Differin Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 8.1 Miscellaneous Dermatological Drugs Market: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 8.2 Propecia Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 9.1 Leading Companies in the Dermatological Drugs Market: Revenues ($m) and Market Shares (%), 2010
Table 10.1 The Infectious Skin Disease Drug Pipeline, 2011
Table 10.2 Pipeline Products for the Treatment of Dermatitis, 2011
Table 10.3 Pipeline Products for the Treatment of Psoriasis, 2011
Table 10.4 Pipeline Products for the Treatment of Acne, 2011
Table 10.5 Pipeline Products for Other Skin Conditions, 2011
Table 11.1 Sales Rankings and Market Shares (%) For Nine Leading National Markets, 2010, 2016 & 2022
Table 11.2 Dermatological Market Revenues: Growth ($m, %) of Leading National Markets, 2010-2022
Table 11.3 Dermatological Drug Market Forecasts for Nine Leading National Markets: Sales ($m), AGR (%), CAGR (%), 2010-2016
Table 11.4 Dermatological Drug Market Forecasts For Nine Leading National Markets: Sales ($m), AGR (%), CAGR (%), 2017-2022
Table 11.5 US: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 11.6 Japan: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 11.7 Germany: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 11.8 France: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 11.9 UK: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 11.10 Italy: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 11.11 Spain: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 11.12 India: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 11.13 China: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 12.1 SWOT Analysis of the Dermatological Drug Market, 2012
List of Figures
Figure 3.1 Dermatological Drug Market Shares (%) by Segment, 2010
Figure 3.2 The World Dermatological Drug Market: Sales Forecast ($m), 2010-2022
Figure 3.3 Sales Forecasts ($m) for Segments of the World Dermatological Drug Market, 2010-2022
Figure 4.1 Leading Infectious Skin Disease Drug Market Shares (%), 2010
Figure 4.2 World Infectious Skin Disease Drug Market Forecast ($m), 2010-2022
Figure 4.3 Leading Infectious Skin Disease Drugs: Market Share Forecast s (%), 2010-2022
Figure 4.4 Leading Infectious Skin Disease Drugs: Sales Forecasts ($m), 2010-2022
Figure 4.5 Valtrex Sales Forecast ($m), 2010-2022
Figure 4.6 Zovirax Sales Forecast ($m), 2010-2022
Figure 4.7 Aldara Sales Forecast ($m), 2010-2022
Figure 4.8 Bactroban Sales Forecast ($m), 2010-2022
Figure 4.9 Lamisil Sales Forecast ($m), 2010-2022
Figure 5.1 Leading Dermatitis Drugs: Market Shares (%), 2010
Figure 5.2 Leading Dermatitis Drugs: Sales Forecasts ($m), 2010-2022
Figure 5.3 Leading Dermatitis Drugs: Market Share Forecasts (%), 2010-2022
Figure 5.4 Protopic Sales Forecast ($m), 2010-2022
Figure 5.5 Elidel Sales Forecast ($m), 2010-2022
Figure 5.6 Elocon Sales Forecast ($m), 2010-2022
Figure 5.7 Clobex Sales Forecast ($m), 2010-2022
Figure 5.8 Soriatane Sales Forecast ($m), 2010-2022
Figure 6.1 Leading Psoriasis Drugs: Market Shares (%), 2010
Figure 6.2 World Psoriasis Drug Market Forecast ($m), 2010-2022
Figure 6.3 Leading Psoriasis Drugs: Sales Forecasts ($m), 2010-2022
Figure 6.4 Leading Psoriasis Drugs: Market Share Forecasts (%), 2010-2022
Figure 6.5 Enbrel Sales Forecast ($m), 2010-2022
Figure 6.6 Humira Sales Forecast ($m), 2010-2022
Figure 6.7 Stelara Sales Forecast ($m), 2010-2022
Figure 6.8 Remicade Sales Forecast ($m), 2010-2022
Figure 6.9 Daivobet Sales Forecast ($m), 2010-2022
Figure 6.10 Taclonex Sales Forecast ($m), 2010-2022
Figure 6.11 Dovonex Sales Forecast ($m), 2010-2022
Figure 7.1 Leading Acne Drugs: Market Shares (%), 2010
Figure 7.2 World Acne Drug Market Forecast ($m), 2010-2022
Figure 7.3 Leading Acne Drugs: Sales Forecasts ($m), 2010-2022
Figure 7.4 Leading Acne Drugs: Market Share Forecasts (%), 2010-2022
Figure 7.5 Claravis Sales Forecast ($m), 2010-2022
Figure 7.6 Solodyn Sales Forecast ($m), 2010-2022
Figure 7.7 Diane Sales Forecast ($m), 2010-2022
Figure 7.8 Duac Sales Forecast ($m), 2010-2022
Figure 7.9 Doryx Sales Forecast ($m), 2010-2022
Figure 7.10 Differin Sales Forecast ($m), 2010-2022
Figure 8.1 World Miscellaneous Dermatological Drugs Market: Sales Forecast ($m), 2010-2022
Figure 8.2 Propecia Sales Forecast ($m), 2010-2022
Figure 9.1 Companies in the Dermatological Drug Sector: Market Shares (%), 2010
Figure 11.1 Leading National Markets: Revenue Shares (%), 2010
Figure 11.2 Dermatological Drug Sales Forecasts for US and Japanese Markets ($m), 2010-2022
Figure 11.3 Dermatological Drug Sales Forecasts for Leading European, Indian and Chinese Markets ($m), 2010-2022
Figure 11.4 US: Sales Forecast ($m), 2010-2022
Figure 11.5 Japan: Sales Forecast ($m), 2010-2022
Figure 11.6 Germany: Sales Forecast ($m), 2010-2022
Figure 11.7 France: Sales Forecast ($m), 2010-2022
Figure 11.8 UK: Sales Forecast ($m), 2010-2022
Figure 11.9 Italy: Sales Forecast ($m), 2010-2022
Figure 11.10 Spain: Sales Forecast ($m), 2010-2022
Figure 11.11 India: Sales Forecast ($m), 2010-2022
Figure 11.12 China: Sales Forecast ($m), 2010-2022
Companies Listed
3SBio
Abbott Laboratories
Actavis
Actelion Pharmaceuticals
Albert Einstein College of Medicine
Allergan
Almirall
Altana
American Academy of Dermatology
Amgen
Anacor Pharmaceuticals
AndroScience Corp
AnGesMG
Anterios
Antigenics
Apotex
Apotheca
Applied Genetics
aRigen Pharmaceuticals
Astellas Pharma
Astion
Asubio Pharma
Aurobindo Pharma
Barr
Basilea
Bayer
Bio3 Research
BioCryst Pharmaceuticals
BioMAS
Biomed Research & Technologies
Biotest
Biovail
Birken
Braintree Laboratories
Bristol-Myers Squibb
British Association of Dermatologists
Can-Fite Biopharma
Celgene Corporation
Centocor Ortho Biotech
Cipher Pharmaceuticals
CollaGenex Pharmaceuticals
Cosmo Pharmaceuticals
Creabilis Therapeutics
Critical Therapeutics
Cytotech Labs
DAVA Pharmaceuticals
DeNova Research
Derma Sciences
Dow Pharmaceutical Sciences
Dr. Reddy's Laboratories
DUSA Pharmaceuticals
Eisai
Eli Lilly
Epiphany
European Medicines Agency (EMEA/EMA)
Foamix
Food and Drug Administration (US FDA)
Forward Pharma
Fougera
G&W Labs
Galderma
Gene Signal International
Genzyme
GlaxoSmithKline (GSK)
Glenmark
Graceway Pharmaceuticals
Gruenenthal
Hanwha Pharmaceutical
Hetero Drugs
Immune Control
Immune Control
Immune Technologies & Medicine GmbH
Impax Laboratories
Incyte Corporation
Inhibitex
iNova Pharmaceuticals
INSERM
Intendis
Isotechnika Pharma
Jannsen Biotech
Janssen-Cilag
Johnson & Johnson (J&J)
Kaken Pharmaceutical
KV Pharmaceuticals
Kythera Biopharmaceuticals
L.A.L. Clinica Pesquisa e Desenvolvimento
Laboratorio Teuto Brasiliero
Laboratorios Goulart
LEO Pharma
Ligand Pharmaceuticals
L'Oréal
Lupin
Maruho Co.
Matrix Laboratories
Mayne
Meda AB
Medicines and Healthcare Products Regulatory Agency (MHRA, UK)
Medicis
Medimetriks
Medivir AB
Merck & Co.
Merz Pharmaceuticals
Mitos Pharmaceuticals
Mitsubishi Tanabe
Moberg Derma
Mochida Pharmaceutical Co.
Morria
Mount Sinai School of Medicine
Mycenax Biotech
Mylan
NanoBio Corporation
Nanodermatology Society
National Cancer Institute (US)
National Health Service (NHS, UK)
National Institute for Health and Clinical Excellence (NICE, UK)
National Institute of Allergy and Infectious Diseases (NIAID, US)
Nestlé
Nitric Biotherapeutics
Northwestern University
Novartis
Nycomed
Onset Therapeutics
Oplon-Pure Science
Orient Pharma
Ortho Dermatologics
OSI Pharmaceuticals
Par Pharmaceuticals
Paratek
Perrigo
Pfizer
PhotoCure
Pliva
Provectus Pharmaceuticals
QuatRx Pharmaceuticals
Rabin Medical Centre
Ranbaxy
Regeneron Pharmaceuticals
Roche
Roxane Laboratories
Sandoz (part of Novartis)
Sanofi
Schering-Plough
Senetek
Serentis
Sheba Medical Centre
Shinogi
SkinMedica
Sol-Gel
Star Pharma
Stiefel
Summit
Takeda Pharmaceuticals
Taro Pharmaceutical Industries
Teva Pharmaceutical Industries
Tolmar
Tufts Medical Center
University of British Columbia
University of California
Valeant Pharmaceuticals
Vascular Biogenic
Vicept
Visonac
Warner Chilcott
Watson Laboratories
Welichem Biotech
Zalicus
Zurita Laboratorio Farmaceutico
To order this report:
Drug and Medication Industry: Dermatological Drugs: World Market Prospects 2012-2022
More Market Research Report
Check our Industry Analysis and Insights
CONTACT:Nicolas BombourgReportlinkerEmail: [email protected]US: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
Advertisement
Dermatological Drugs: World Market Prospects 2012-2022
http://www.reportlinker.com/p0788690/Dermatological-Drugs-World-Market-Prospects-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
Advertisement
Report Details
Where are dermatological treatments heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions.
This study assesses drugs to treat human skin disorders. You discover sales predictions at world market, therapeutic submarket, product and national levels to 2022.
How will 24 leading drugs - Valtrex, Zovirax, Protopic, Enbrel and others - perform from 2012? Our report gives you business research and analysis with many sales forecasts.
Also, you see forecasting of five derma submarkets to 2022, finding potential revenues:
• Dermatitis
• Psoriasis
• Acne
• Infectious skin diseases
• Miscellaneous dermatologics.
What does the future hold? The pharma industry has potential for improved treatments and increased revenues from dermatological agents. The R&D pipeline is strong.
Our report discusses GSK, Galderma, Amgen, Abbott, J&J and other pharmaceutical companies, assessing prospects of the industry and market.
Many commercial opportunities in treating skin disorders remain, including increased revenues. You can investigate the future of that area now.
Visiongain's study provides data, analysis and opinion aiming to benefit your research, calculations, meetings and presentations. You find answers in our work.
Revenue forecasts, market shares, developmental trends and discussions
In our report you find revenue forecasting, growth rates and market shares. Also, you have qualitative analyses (including SWOT) and discussion of R&D activities. You receive 121 tables and charts and a research interview.
Advantages of Dermatological Drugs: World Market Prospects 2012-2022 for your work
In particular, this study gives you the following knowledge on the topic:
• Find potential revenues to 2022 for the world market and submarkets
• Discover revenue forecasts to 2022 for 24 leading products
• See market forecasting to 2022 for the US, Japan, the EU5, China and India
• Assess leading companies, discovering activities and outlooks
• Review R&D, seeing pipeline trends
• Investigate competition and opportunities influencing sales
• Find out what will stimulate and restrain the industry and market
• View opinion from the sector, receiving primary research.
There, you find a distinctive mix of quantitative and qualitative analyses with independent predictions. Without our report, you could miss out on information that your competitors are using.
We investigate commercial applications of dermatology, helping you to stay ahead.
Gain business research and analysis for the treatment of skin disorders
Our study is for everybody needing industry and market analyses for dermatological drugs. Find data, trends and answers. Avoid missing out - please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Table of Contents
1. Executive Summary
1.1 World Dermatological Drug Market: Overview of Findings
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods
2. Introduction to Dermatological Disorders and Their Treatments
2.1 An Introduction to Dermatology
2.1.1 The Structure of the Skin
2.1.2 Hair
2.1.3 Nails
2.1.4 Sweat and Sebaceous Glands
2.2 Functions of the Skin
2.2.1 Protection
2.2.2 Sensation
2.2.3 Vitamin D Synthesis
2.2.4 Temperature Regulation and Heat Insulation
2.2.5 Storage
2.2.6 Prevention of Water Loss
2.3 Common Skin Diseases
2.4 An Introduction to Acne Vulgaris
2.4.1 Acne Conglobata
2.4.2 Acne Fulminans
2.4.3 Gram-Negative Folliculitis
2.4.4 Pyoderma Faciale
2.4.5 Causes of Acne
2.5 An Introduction to Dermatitis
2.5.1 Atopic Dermatitis
2.5.2 Contact Dermatitis
2.5.3 Seborrheic Dermatitis
2.5.4 Nummular Dermatitis
2.5.5 Perioral Dermatitis
2.6 An Introduction to Psoriasis
2.6.1 Plaque Psoriasis
2.6.2 Guttate Psoriasis
2.6.3 Pustular Psoriasis
2.6.4 Inverse Psoriasis
2.6.5 Erythrodermic Psoriasis
2.7 An Introduction to Rosacea
2.7.1 Erythematotelangiectatic Rosacea
2.7.2 Papulopustular Rosacea
2.7.3 Phymatous Rosacea
2.7.4 Ocular Rosacea
2.8 An Introduction to Alopecia
2.8.1 Alopecia Areata
2.8.2 Alopecia Totalis
2.8.3 Alopecia Universalis
2.8.4 Androgenetic Alopecia
2.8.5 Alopecia Barbae
2.8.6 Alopecia Mucinosa
2.8.7 Traction Alopecia
2.8.8 Anagen Effluvium
2.8.9 Telogen Effluvium
2.9 An Introduction to Infectious Diseases of the Skin
2.9.1 Bacterial Skin Infections
2.9.1.1 Impetigo
2.9.1.2 Folliculitis
2.9.1.3 Cellulitis
2.9.1.4 Furunculosis
2.9.1.5 Carbuncle
2.9.2 Fungal Skin Infections
2.9.2.1 Tinea Pedis (Athlete's Foot)
2.9.2.2 Tinea Unguium (Ringworm of the Nails)
2.9.2.3 Tinea Corporis (Ringworm of the Skin)
2.9.2.4 Tinea Capitis (Scalp Ringworm)
2.9.2.5 Kerions
2.9.3 Viral Skin Infections
2.9.3.1 Molluscum Contagiosum
2.9.3.2 Warts
2.9.3.3 Herpes Simplex
2.9.3.4 Chickenpox
2.9.3.5 Herpes Zoster
2.10 Common Skin Treatments
2.10.1 Creams and Semisolid Emulsions
2.10.2 Ointments
2.10.3 Lotions
2.10.4 Solutions
2.10.5 Occlusive Therapy
2.10.6 Cleansing Agents
2.10.7 Protecting Powders and Hydrophilic Polymer
2.10.8 Anti-Infective Agents
2.10.9 Anti-Inflammatory Agents
3. The World Dermatological Drug Market, 2012-2022
3.1 The World Dermatological Drug Market in 2010
3.2 The Infectious Skin Diseases Market Dominates the World Dermatological Drug Market
3.3 Biologic Agents for the Treatment of Psoriasis Are the Leading Drugs in the Dermatologics Market
3.4 The Changing Landscape of the Dermatological Drug Market
3.5 The World Dermatological Drug Market: Forecasts, 2012-2022
3.5.1 Market Shares of Leading Segments
3.5.1.1 The Psoriasis Market Will Achieve the Greatest Increase in Market Share
3.6 The Future of the Dermatological Drug Market
3.6.1 Blockbuster Sales - Hard to Achieve?
4. The Infectious Skin Diseases Drug Market, 2012-2022
4.1 The Infectious Skin Diseases Drug Market in 2010
4.1.1 Antiviral Products Led the Dermatological Anti-Infectives Market in 2010
4.1.2 Systemic Antiviral Products Lead the Infectious Skin Diseases Drug Market
4.2 World Infectious Skin Diseases Drug Market Forecast, 2012-2022
4.3 Valtrex (Valacyclovir)
4.3.1 Patent Expiry and the End of Blockbuster Revenues
4.3.2 Valtrex Sales Will Continue to Decline
4.4 Zovirax
4.4.1 Zovirax Sales Forecast, 2012-2022
4.5 Aldara/Zyclara (Imiquimod)
4.5.1 Patent Expiry and Other Challenges
4.5.2 Lifecycle Management
4.5.3 Aldara Sales Forecast, 2012-2022
4.6 Bactroban (Mupirocin)
4.6.1 Bactroban Sales Forecast, 2012-2022
4.7 Lamisil (Terbinafine)
4.7.1 Lamisil Sales Forecast, 2012-2022
4.8 The Infectious Skin Diseases Market - Summary
5. The Dermatitis Drug Market, 2012-2022
5.1 The Dermatitis Drug Market in 2010
5.1.1 Corticosteroids are the Leading Dermatitis Treatment
5.2 Dermatitis Drug Market Forecast, 2012-2022
5.3 Protopic (Tacrolimus)
5.3.1 Protopic Sales Forecast, 2012-2022
5.3.2 Protopic Benefits from Expanded Indication
5.3.3 Will Protopic's Strong Sales Increase Recur?
5.4 Elidel (Pimecrolimus)
5.4.1 Elidel Rights Sold
5.4.2 Regulatory Matters
5.4.3 Elidel Sales Forecast, 2012-2022
5.4.4 Expanding Elidel Indications May Stimulate Sales Growth
5.5 Elocon (Mometasone Furoate)
5.5.1 Elocon Sales Forecast, 2012-2022
5.6 Clob X/Clobex (Clobetasol Propionate)
5.6.1 Clobex Sales Increase
5.7 Soriatane (Acitretin)
5.8 The Dermatitis Drug Market - Summary
6. The Psoriasis Drug Market, 2012-2022
6.1 The Psoriasis Drug Market in 2010
6.2 Biologic Drugs Lead the Psoriasis Market
6.3 World Psoriasis Drug Market Forecast, 2012-2022
6.3.1 Growth in the Psoriasis Drug Market Will Be Spurred by Increasing Use of Biologics
6.4 Enbrel (Etanercept)
6.4.1 Enbrel Continued to Lead the Psoriasis Market in 2010
6.4.2 Enbrel Sales Forecast, 2012-2022
6.4.3 Enbrel in Competition with Humira and Stelara
6.4.4 Biosimilar Competition
6.4.5 Competition from Pipeline Products
6.5 Humira (Adalimumab)
6.5.1 Humira Has Gained Market Acceptance
6.6 Stelara (Ustekinumab)
6.6.1 Stelara Will Achieve Strong Growth in the Psoriasis Market
6.7 Remicade (Infliximab)
6.8 Topical Treatments for Psoriasis
6.9 Daivobet (Calcipotriol and Betamethasone)
6.9.1 Daivobet Leads the Topical Psoriasis Market
6.9.2 Daivobet Sales Will Grow Until 2020
6.10 Taclonex (Calcipotriol and Betamethasone)
6.10.1 Taclonex Sales Forecast, 2012-2022
6.10.2 Taclonex May Face Generic Competition
6.11 Dovonex (Calcipotriol)
6.11.1 Patent Expiration and Generic Competition
6.11.2 Dovonex Sales Forecast, 2012-2022
6.12 The World Psoriasis Drug Market - Summary
7. The Acne Drug Market, 2012-2022
7.1 Available Treatments and Unmet Needs
7.2 Leading Products in the Acne Drug Market, 2010
7.3 World Acne Drug Market Forecast, 2012-2022
7.4 Claravis (Isotretinoin)
7.4.1 Claravis Sales Forecast, 2012-2022
7.5 Solodyn (Minocycline)
7.5.1 Solodyn Led the World Acne Drug Market in 2010
7.5.2 Solodyn Sales Forecast, 2012-2022
7.6 Diane (Cyproterone and Ethinylestradiol)
7.6.1 Diane Sales Forecast, 2012-2022
7.7 Duac (Clindamycin and Benzoyl Peroxide)
7.8 Doryx (Doxycycline Hyclate)
7.8.1 Doryx Sales Forecast, 2012-2022
7.8.2 Lifecycle Management of Doryx
7.9 Differin (Adapalene)
7.9.1 Differin Sales Forecast, 2012-2022
7.9.2 Lifecycle Management of Differin
7.10 Combination Treatments for Acne
7.10.1 Epiduo (Adapalene and Benzoyl Peroxide)
7.10.2 Ziana (Tretinoin and Clindamycin)
7.10.3 Veltin (Tretinoin and Clindamycin)
7.11 The World Acne Drug Market - Summary
8. Miscellaneous Dermatological Drugs, 2012-2022
8.1 The Miscellaneous Dermatological Drugs Market in 2010
8.2 Miscellaneous Dermatological Drugs: Market Forecast, 2012-2022
8.3 Propecia (Finasteride)
8.3.1 Propecia Sales Will Fall
8.3.2 Propecia Faces Competition from Rogaine/Regaine
8.4 The Miscellaneous Dermatological Drugs Market - Summary
9. Leading Companies in the Dermatological Drug Market
9.1 Prominent Companies in the Dermatological Drug Market, 2010
9.2 GlaxoSmithKline
9.3 Galderma
9.4 Amgen
9.5 Abbott
9.6 Johnson & Johnson
9.7 Medicis Pharmaceutical
9.8 LEO Pharma
9.9 Warner Chilcott
9.10 Valeant
9.11 Roche
9.12 Sanofi
9.13 Bayer
9.14 Merck & Co.
9.15 Meda AB
9.16 Novartis
9.17 Companies in the Dermatological Drug Market - Summary
10. The R&D Pipeline for Dermatological Pharmaceuticals
10.1 The Size of the Dermatological Pharmaceuticals Market Encourages R&D
10.2 New Technology in R&D Pipeline Activities
10.2.1 Reformulation
10.2.2 Combination Treatments
10.2.3 New Mechanisms and Drug Delivery Technologies
10.3 Potential Market Entrants
10.4 The Infectious Skin Disease Pipeline
10.4.1 NB-001
10.5 The Dermatitis Pipeline
10.5.1 MRX6
10.6 The Psoriasis Pipeline
10.6.1 Briakinumab
10.6.2 Apremilast
10.6.3 AN2728
10.6.4 Tofacitinib
10.7 The Acne Pipeline
10.7.1 Visonac
10.7.2 Acne Vaccine
10.7.3 ACAT Inhibitor
10.8 The Miscellaneous Dermatological Drugs Pipeline
10.9 PEP005
10.10 Innovation Rules for Early-Stage Pipeline Drugs
11. National Market Forecasts, 2012-2022
11.1 Leading National Markets for Dermatological Drugs, 2010
11.2 Leading National Markets for Dermatological Drugs: Forecasts, 2012-2022
11.3 The Dermatological Drug Market in the US, 2012-2022
11.4 The Dermatological Drug Market in Japan, 2012-2022
11.5 The Dermatological Drug Market in Germany, 2012-2022
11.6 The Dermatological Drug Market in France, 2012-2022
11.7 The Dermatological Drug Market in the UK, 2012-2022
11.8 The Dermatological Drug Market in Italy, 2012-2022
11.9 The Dermatological Drug Market in Spain, 2012-2022
11.10 The Dermatological Drug Market in India, 2012-2022
11.11 The Dermatological Drug Market in China, 2012-2022
12. Qualitative Analysis of the World Dermatological Drug Market, 2012
12.1 SWOT Analysis
12.2 Market Drivers
12.3 Market Restraints
12.4 There is Scope for Market Development and Expansion
12.5 Advances in Research are Likely to Bring Benefits to the Market
12.6 Downward Pressures on Drug Prices Affect the Industry
12.7 Competition in the Dermatological Drug Market Will Intensify
12.8 Substitutes
12.9 How Great is the Threat from Generic Drugs in the Dermatological Sector?
13. Research Interview
13.1 Interview with Dr Adam Friedman
13.1.1 Unmet Needs in the Dermatological Drugs Marks
13.1.2 Key Areas for Dermatological Research
13.1.3 Pipeline Dermatological Drug Products
13.1.4 The Future Role of Nanotechnology in Dermatological Drugs
13.1.5 Challenges in Advancing Dermatological Treatments
14. Conclusions
14.1 The World Dermatological Drug Market Will Experience Sales Growth
14.2 Will The Infectious Skin Diseases Market Continue to Dominate the Overall Market?
14.3 Dermatological Treatments: Companies Prominent in that Industry and Market
14.4 The Need for New Therapies for the Treatment of Dermatitis
14.5 Combination Treatments and Lifecycle Management in the Acne Market
14.6 Biologics Will Drive Growth in the Psoriasis Market
14.7 Overall World Dermatological Drug Market Growth Will Continue
List of Tables
Table 3.1 The World Dermatological Drugs: Market Segments, Revenues ($m) and Market Shares (%), 2010
Table 3.2 Leading Dermatological Drugs ($m), 2010
Table 3.3 World Dermatological Drug Market: Sales Forecasts by Segment ($m), AGR (%), CAGR (%), 2010-2016
Table 3.4 World Dermatological Drug Market: Sales Forecasts by Segment ($m), AGR (%), CAGR (%), 2017-2022
Table 3.5 Segments of the World Dermatological Drug Market: Forecasts by Market Share (% of Total Revenues), Rank (By Revenue), 2010, 2016 and 2022
Table 4.1 Leading Drugs for the Treatment of Infectious Skin Diseases ($m), 2010
Table 4.2 Sales ($m) and Market Shares (%) of Infectious Skin Diseases Drugs by Class, 2010
Table 4.3 Infectious Skin Disease Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2010-2016
Table 4.4 Infectious Skin Disease Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2017-2022
Table 4.5 Valtrex Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 4.6 Zovirax Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 4.7 Aldara Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 4.8 Bactroban Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 4.9 Lamisil Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 5.1 Leading Drugs ($m) for the Treatment of Dermatitis, 2010
Table 5.2 Sales ($m) and Market Shares (%) of Dermatitis Drugs by Class, 2010
Table 5.3 Dermatitis Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2010-2016
Table 5.4 Dermatitis Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2017-2022
Table 5.5 Protopic Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 5.6 Elidel Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 5.7 Elocon Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 5.8 Clobex Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 5.9 Soriatane Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 6.1 Market Leading Drugs ($m) for the Treatment of Psoriasis, 2010
Table 6.2 Psoriasis Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2010-2016
Table 6.3 Psoriasis Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2017-2022
Table 6.4 Enbrel Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 6.5 Humira Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 6.6 Stelara Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 6.7 Remicade Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 6.8 Daivobet Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 6.9 Taclonex Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 6.10 Dovonex Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 7.1 Acne Drug Sales ($m) by Class, 2010
Table 7.2 Market Leading Drugs ($m) for the Treatment of Acne, 2010
Table 7.3 Acne Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2010-2016
Table 7.4 Acne Drug Sales Forecasts ($m), Growth Rates (%), CAGR (%), 2017-2022
Table 7.5 Claravis Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 7.6 Solodyn Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 7.7 Diane Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 7.8 Duac Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 7.9 Doryx Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 7.10 Differin Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 8.1 Miscellaneous Dermatological Drugs Market: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 8.2 Propecia Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 9.1 Leading Companies in the Dermatological Drugs Market: Revenues ($m) and Market Shares (%), 2010
Table 10.1 The Infectious Skin Disease Drug Pipeline, 2011
Table 10.2 Pipeline Products for the Treatment of Dermatitis, 2011
Table 10.3 Pipeline Products for the Treatment of Psoriasis, 2011
Table 10.4 Pipeline Products for the Treatment of Acne, 2011
Table 10.5 Pipeline Products for Other Skin Conditions, 2011
Table 11.1 Sales Rankings and Market Shares (%) For Nine Leading National Markets, 2010, 2016 & 2022
Table 11.2 Dermatological Market Revenues: Growth ($m, %) of Leading National Markets, 2010-2022
Table 11.3 Dermatological Drug Market Forecasts for Nine Leading National Markets: Sales ($m), AGR (%), CAGR (%), 2010-2016
Table 11.4 Dermatological Drug Market Forecasts For Nine Leading National Markets: Sales ($m), AGR (%), CAGR (%), 2017-2022
Table 11.5 US: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 11.6 Japan: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 11.7 Germany: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 11.8 France: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 11.9 UK: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 11.10 Italy: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 11.11 Spain: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 11.12 India: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 11.13 China: Sales Forecast ($m), AGR (%), CAGR (%), 2010-2022
Table 12.1 SWOT Analysis of the Dermatological Drug Market, 2012
List of Figures
Figure 3.1 Dermatological Drug Market Shares (%) by Segment, 2010
Figure 3.2 The World Dermatological Drug Market: Sales Forecast ($m), 2010-2022
Figure 3.3 Sales Forecasts ($m) for Segments of the World Dermatological Drug Market, 2010-2022
Figure 4.1 Leading Infectious Skin Disease Drug Market Shares (%), 2010
Figure 4.2 World Infectious Skin Disease Drug Market Forecast ($m), 2010-2022
Figure 4.3 Leading Infectious Skin Disease Drugs: Market Share Forecast s (%), 2010-2022
Figure 4.4 Leading Infectious Skin Disease Drugs: Sales Forecasts ($m), 2010-2022
Figure 4.5 Valtrex Sales Forecast ($m), 2010-2022
Figure 4.6 Zovirax Sales Forecast ($m), 2010-2022
Figure 4.7 Aldara Sales Forecast ($m), 2010-2022
Figure 4.8 Bactroban Sales Forecast ($m), 2010-2022
Figure 4.9 Lamisil Sales Forecast ($m), 2010-2022
Figure 5.1 Leading Dermatitis Drugs: Market Shares (%), 2010
Figure 5.2 Leading Dermatitis Drugs: Sales Forecasts ($m), 2010-2022
Figure 5.3 Leading Dermatitis Drugs: Market Share Forecasts (%), 2010-2022
Figure 5.4 Protopic Sales Forecast ($m), 2010-2022
Figure 5.5 Elidel Sales Forecast ($m), 2010-2022
Figure 5.6 Elocon Sales Forecast ($m), 2010-2022
Figure 5.7 Clobex Sales Forecast ($m), 2010-2022
Figure 5.8 Soriatane Sales Forecast ($m), 2010-2022
Figure 6.1 Leading Psoriasis Drugs: Market Shares (%), 2010
Figure 6.2 World Psoriasis Drug Market Forecast ($m), 2010-2022
Figure 6.3 Leading Psoriasis Drugs: Sales Forecasts ($m), 2010-2022
Figure 6.4 Leading Psoriasis Drugs: Market Share Forecasts (%), 2010-2022
Figure 6.5 Enbrel Sales Forecast ($m), 2010-2022
Figure 6.6 Humira Sales Forecast ($m), 2010-2022
Figure 6.7 Stelara Sales Forecast ($m), 2010-2022
Figure 6.8 Remicade Sales Forecast ($m), 2010-2022
Figure 6.9 Daivobet Sales Forecast ($m), 2010-2022
Figure 6.10 Taclonex Sales Forecast ($m), 2010-2022
Figure 6.11 Dovonex Sales Forecast ($m), 2010-2022
Figure 7.1 Leading Acne Drugs: Market Shares (%), 2010
Figure 7.2 World Acne Drug Market Forecast ($m), 2010-2022
Figure 7.3 Leading Acne Drugs: Sales Forecasts ($m), 2010-2022
Figure 7.4 Leading Acne Drugs: Market Share Forecasts (%), 2010-2022
Figure 7.5 Claravis Sales Forecast ($m), 2010-2022
Figure 7.6 Solodyn Sales Forecast ($m), 2010-2022
Figure 7.7 Diane Sales Forecast ($m), 2010-2022
Figure 7.8 Duac Sales Forecast ($m), 2010-2022
Figure 7.9 Doryx Sales Forecast ($m), 2010-2022
Figure 7.10 Differin Sales Forecast ($m), 2010-2022
Figure 8.1 World Miscellaneous Dermatological Drugs Market: Sales Forecast ($m), 2010-2022
Figure 8.2 Propecia Sales Forecast ($m), 2010-2022
Figure 9.1 Companies in the Dermatological Drug Sector: Market Shares (%), 2010
Figure 11.1 Leading National Markets: Revenue Shares (%), 2010
Figure 11.2 Dermatological Drug Sales Forecasts for US and Japanese Markets ($m), 2010-2022
Figure 11.3 Dermatological Drug Sales Forecasts for Leading European, Indian and Chinese Markets ($m), 2010-2022
Figure 11.4 US: Sales Forecast ($m), 2010-2022
Figure 11.5 Japan: Sales Forecast ($m), 2010-2022
Figure 11.6 Germany: Sales Forecast ($m), 2010-2022
Figure 11.7 France: Sales Forecast ($m), 2010-2022
Figure 11.8 UK: Sales Forecast ($m), 2010-2022
Figure 11.9 Italy: Sales Forecast ($m), 2010-2022
Figure 11.10 Spain: Sales Forecast ($m), 2010-2022
Figure 11.11 India: Sales Forecast ($m), 2010-2022
Figure 11.12 China: Sales Forecast ($m), 2010-2022
Companies Listed
3SBio
Abbott Laboratories
Actavis
Actelion Pharmaceuticals
Albert Einstein College of Medicine
Allergan
Almirall
Altana
American Academy of Dermatology
Amgen
Anacor Pharmaceuticals
AndroScience Corp
AnGesMG
Anterios
Antigenics
Apotex
Apotheca
Applied Genetics
aRigen Pharmaceuticals
Astellas Pharma
Astion
Asubio Pharma
Aurobindo Pharma
Barr
Basilea
Bayer
Bio3 Research
BioCryst Pharmaceuticals
BioMAS
Biomed Research & Technologies
Biotest
Biovail
Birken
Braintree Laboratories
Bristol-Myers Squibb
British Association of Dermatologists
Can-Fite Biopharma
Celgene Corporation
Centocor Ortho Biotech
Cipher Pharmaceuticals
CollaGenex Pharmaceuticals
Cosmo Pharmaceuticals
Creabilis Therapeutics
Critical Therapeutics
Cytotech Labs
DAVA Pharmaceuticals
DeNova Research
Derma Sciences
Dow Pharmaceutical Sciences
Dr. Reddy's Laboratories
DUSA Pharmaceuticals
Eisai
Eli Lilly
Epiphany
European Medicines Agency (EMEA/EMA)
Foamix
Food and Drug Administration (US FDA)
Forward Pharma
Fougera
G&W Labs
Galderma
Gene Signal International
Genzyme
GlaxoSmithKline (GSK)
Glenmark
Graceway Pharmaceuticals
Gruenenthal
Hanwha Pharmaceutical
Hetero Drugs
Immune Control
Immune Control
Immune Technologies & Medicine GmbH
Impax Laboratories
Incyte Corporation
Inhibitex
iNova Pharmaceuticals
INSERM
Intendis
Isotechnika Pharma
Jannsen Biotech
Janssen-Cilag
Johnson & Johnson (J&J)
Kaken Pharmaceutical
KV Pharmaceuticals
Kythera Biopharmaceuticals
L.A.L. Clinica Pesquisa e Desenvolvimento
Laboratorio Teuto Brasiliero
Laboratorios Goulart
LEO Pharma
Ligand Pharmaceuticals
L'Oréal
Lupin
Maruho Co.
Matrix Laboratories
Mayne
Meda AB
Medicines and Healthcare Products Regulatory Agency (MHRA, UK)
Medicis
Medimetriks
Medivir AB
Merck & Co.
Merz Pharmaceuticals
Mitos Pharmaceuticals
Mitsubishi Tanabe
Moberg Derma
Mochida Pharmaceutical Co.
Morria
Mount Sinai School of Medicine
Mycenax Biotech
Mylan
NanoBio Corporation
Nanodermatology Society
National Cancer Institute (US)
National Health Service (NHS, UK)
National Institute for Health and Clinical Excellence (NICE, UK)
National Institute of Allergy and Infectious Diseases (NIAID, US)
Nestlé
Nitric Biotherapeutics
Northwestern University
Novartis
Nycomed
Onset Therapeutics
Oplon-Pure Science
Orient Pharma
Ortho Dermatologics
OSI Pharmaceuticals
Par Pharmaceuticals
Paratek
Perrigo
Pfizer
PhotoCure
Pliva
Provectus Pharmaceuticals
QuatRx Pharmaceuticals
Rabin Medical Centre
Ranbaxy
Regeneron Pharmaceuticals
Roche
Roxane Laboratories
Sandoz (part of Novartis)
Sanofi
Schering-Plough
Senetek
Serentis
Sheba Medical Centre
Shinogi
SkinMedica
Sol-Gel
Star Pharma
Stiefel
Summit
Takeda Pharmaceuticals
Taro Pharmaceutical Industries
Teva Pharmaceutical Industries
Tolmar
Tufts Medical Center
University of British Columbia
University of California
Valeant Pharmaceuticals
Vascular Biogenic
Vicept
Visonac
Warner Chilcott
Watson Laboratories
Welichem Biotech
Zalicus
Zurita Laboratorio Farmaceutico
To order this report:
Drug and Medication Industry: Dermatological Drugs: World Market Prospects 2012-2022
More Market Research Report
Check our Industry Analysis and Insights
CONTACT:Nicolas BombourgReportlinkerEmail: [email protected]US: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
